Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic
  • Search Hotels in Sunnyvale

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

SUNOSI for Obstructive Sleep Apnea (OSA) Market Research 2024: Size, Regulatory Milestones, Patents, Sales Forecasts, and Insights, 2019-2032 - ResearchAndMarkets.com

The "SUNOSI Market Size, Forecast, and Market Insight - 2032" report has been added to ResearchAndMarkets.com's offering.

"SUNOSI Market Size, Forecast, and Market Insights, 2032" report provides comprehensive insights about SUNOSI for Obstructive sleep apnea (OSA) in the six major markets. A detailed picture of the SUNOSI for OSA in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom for the study period 2019-2032 is provided in this report along with a detailed description of the SUNOSI for OSA.

SUNOSI is a dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) and is indicated to improve wakefulness in adults living with EDS due to narcolepsy or OSA. In 2014, Jazz Pharmaceuticals acquired a license to develop and commercialize SUNOSI from Aerial Biopharma. Jazz Pharmaceuticals has worldwide development, manufacturing, and commercialization rights to SUNOSI, excluding certain jurisdictions in Asia. SK Biopharmaceuticals, the discoverer of the compound, maintains rights in 12 Asian markets, including Korea, China, and Japan.

The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the SUNOSI market forecast analysis for OSA in the 6MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in OSA.

SUNOSI Analytical Perspective

In-depth SUNOSI Market Assessment

This report provides a detailed market assessment of SUNOSI for Obstructive sleep apnea (OSA) in the six major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom. This segment of the report provides forecasted sales data from 2024 to 2032.

SUNOSI Clinical Assessment

The report provides the clinical trials information of SUNOSI for OSA covering trial interventions, trial conditions, trial status, start and completion dates.

Scope of the Report

  • A comprehensive product overview including the SUNOSI description, mechanism of action, dosage and administration, research and development activities in Obstructive sleep apnea (OSA).
  • Elaborated details on SUNOSI regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the SUNOSI research and development activities in OSA across the United States and Europe.
  • The report also covers the patents information with expiry timeline around SUNOSI.
  • The report contains forecasted sales of SUNOSI for OSA till 2032.
  • Comprehensive coverage of the late-stage emerging therapies for OSA.
  • The report also features the SWOT analysis with analyst views for SUNOSI in OSA.

Key Questions Answered

  • What is the product type, route of administration and mechanism of action of SUNOSI?
  • What is the clinical trial status of the study related to SUNOSI in Obstructive sleep apnea (OSA) and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SUNOSI development?
  • What are the key designations that have been granted to SUNOSI for OSA?
  • What is the forecasted market scenario of SUNOSI for OSA?
  • What are the forecasted sales of SUNOSI in the six major countries, including the United States, Europe (Germany, France, Italy, and Spain) and the United Kingdom?
  • What are the other emerging products available and how are these giving competition to SUNOSI for OSA?
  • Which are the late-stage emerging therapies under development for the treatment of OSA?

Key Topics Covered:

1. Report Introduction

2. SUNOSI Overview in OSA

2.1. Product Detail

2.2. Clinical Development

2.2.1. Clinical studies

2.2.2. Clinical trials information

2.2.3. Safety and efficacy

2.3. Regulatory Milestones

2.4. Other Developmental Activities

2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. SUNOSI Market Assessment

5.1. Market Outlook of SUNOSI in OSA

5.2. 6MM Analysis

5.2.1. Market Size of SUNOSI in the 6MM for OSA

5.3. Country-wise Market Analysis

5.3.1. Market Size of SUNOSI in the United States for OSA

5.3.2. Market Size of SUNOSI in Germany for OSA

5.3.3. Market Size of SUNOSI in France for OSA

5.3.4. Market Size of SUNOSI in Italy for OSA

5.3.5. Market Size of SUNOSI in Spain for OSA

5.3.6. Market Size of SUNOSI in the United Kingdom for OSA

6. SWOT Analysis

7. Analysts' Views

8. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/dhexjs

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Sunnyvale.com & California Media Partners, LLC. All rights reserved.